{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:26:05Z","timestamp":1789471565032,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus L\u00fcbeck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>In the last 2 decades, the optimal management of the axilla in breast cancer patients receiving neoadjuvant chemotherapy (NACT) has been one of the most frequently discussed topics. Little is known about the attitudes of surgeons\/radiologists towards new developments such as targeted axillary dissection. Therefore, the NOGGO conducted a survey to evaluate the current approach to axillary management.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A standardized digital questionnaire was sent out to\u2009&gt;\u2009200 departments in Germany between 7\/2021 and 5\/2022. The survey was supported by EUBREAST.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 116 physicians completed the survey. In cN0 patients scheduled to receive NACT, 89% of respondents recommended sentinel lymph node biopsy (SLNB) after NACT. In case of ypN1mi(sn), 44% advised no further therapy, while 31% proposed ALND and 25% axillary irradiation. 64% of respondents recommended a minimally invasive axillary\u00a0biopsy to cN\u2009+\u2009patients. TAD was used at the departments of 82% of respondents and was offered to all cN\u2009+\u2009patients converting to ycN0 by 57% and only to selected patients, usually based on the number of suspicious nodes at time of presentation, by 43%. The most common marking technique was a clip\/coil. 67% estimated that the detection rate of their marker was very good or good.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This survey shows a heterogenous approach towards axillary management in the neoadjuvant setting in Germany. Most respondents follow current guidelines. Since only two-thirds of respondents experienced the detection rate of the marker used at their department as (very) good, future studies should focus on the comparative evaluation of different marking techniques.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00404-022-06804-w","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T12:42:31Z","timestamp":1665405751000},"page":"1547-1556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Current trends in diagnostic and therapeutic management of the axilla in breast cancer patients receiving neoadjuvant therapy: results of the German-wide NOGGO MONITOR 24 survey"],"prefix":"10.1007","volume":"307","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2374-9482","authenticated-orcid":false,"given":"Maggie","family":"Banys-Paluchowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Untch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Thurmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"K\u00fchn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Gasparri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"de Boniface","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreste Davide","family":"Gentilini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"Stickeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Ditsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Rody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Paluchowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Uwe","family":"Blohmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"6804_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1159\/000524879","volume":"17","author":"N Ditsch","year":"2022","unstructured":"Ditsch N, Woeckel A, Untch M, Jackisch C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer J (2022) AGO recommendations for the diagnosis and treatment of patients with early breast cancer (EBC): update 2022. Breast Care. 17:403","journal-title":"Breast Care."},{"key":"6804_CR2","unstructured":"(2022) NCCN Clinical Practice Guidelines in Oncology, Breast Cancer, Version 2.2022\u2014December 20, 2021, NCCN.org. Accessed 5 Sept 2022"},{"key":"6804_CR3","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1200\/JCO.21.00934","volume":"39","author":"M Brackstone","year":"2021","unstructured":"Brackstone M, Baldassarre FG, Perera FE, Cil T, Chavez Mac Gregor M, Dayes IS, Engel J, Horton JK, King TA, Kornecki A et al (2021) Management of the axilla in early-stage breast cancer: ontario health (cancer care ontario) and ASCO guideline. J Clin Oncol 39:3056\u20133082. https:\/\/doi.org\/10.1200\/JCO.21.00934","journal-title":"J Clin Oncol"},{"key":"6804_CR4","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW et al (2017) effect of axillary dissection vs no axillary dissection on 10\u00a0year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial. JAMA 318:918\u2013926. https:\/\/doi.org\/10.1001\/jama.2017.11470","journal-title":"JAMA"},{"key":"6804_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071565","author":"M Banys-Paluchowski","year":"2021","unstructured":"Banys-Paluchowski M, Gasparri ML, de Boniface J, Gentilini O, Stickeler E, Hartmann S, Thill M, Rubio IT, Di Micco R, Bonci EA et al (2021) Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST-03 AXSANA study. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13071565","journal-title":"Cancers (Basel)"},{"key":"6804_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00404-019-05428-x","volume":"301","author":"M Banys-Paluchowski","year":"2020","unstructured":"Banys-Paluchowski M, Gruber IV, Hartkopf A, Paluchowski P, Krawczyk N, Marx M, Brucker S, Hahn M (2020) Axillary ultrasound for prediction of response to neoadjuvant therapy in the context of surgical strategies to axillary dissection in primary breast cancer: a systematic review of the current literature. Arch Gynecol Obstet 301:341\u2013353. https:\/\/doi.org\/10.1007\/s00404-019-05428-x","journal-title":"Arch Gynecol Obstet"},{"key":"6804_CR7","unstructured":"(2021) Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.4, AWMF Registernummer: 032\u2013045OL, http:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/mammakarzinom\/."},{"key":"6804_CR8","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1055\/a-1889-7883","volume":"82","author":"S Hartmann","year":"2022","unstructured":"Hartmann S, Kuhn T, Hauptmann M, Stickeler E, Thill M, Lux MP, Frohlich S, Ruf F, Loibl S, Blohmer JU et al (2022) Axillary staging after neoadjuvant chemotherapy for initially node-positive breast carcinoma in germany: initial data from the AXSANA study. Geburtshilfe Frauenheilkd 82:932\u2013940. https:\/\/doi.org\/10.1055\/a-1889-7883","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"6804_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000516419","volume":"16","author":"N Ditsch","year":"2021","unstructured":"Ditsch N, Kolberg-Liedtke C, Friedrich M, Jackisch C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P et al (2021) AGO Recommendations for the diagnosis and treatment of patients with early breast cancer: update 2021. Breast Care. 16:214","journal-title":"Breast Care."},{"key":"6804_CR10","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1245\/s10434-018-6429-2","volume":"25","author":"TA Moo","year":"2018","unstructured":"Moo TA, Edelweiss M, Hajiyeva S, Stempel M, Raiss M, Zabor EC, Barrio A, Morrow M (2018) Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? Ann Surg Oncol 25:1488\u20131494. https:\/\/doi.org\/10.1245\/s10434-018-6429-2","journal-title":"Ann Surg Oncol"},{"key":"6804_CR11","unstructured":"(2020) Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.3, AWMF Registernummer: 032\u2013045OL, http:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/mammakarzinom\/."},{"key":"6804_CR12","unstructured":"(2022) Diagnostik und Therapie fr\u00fcher und fortgeschrittener Mammakarzinome. Herausgegeben von der Kommission Mamma (vertreten durch: Wolfgang Janni) der Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie e.V. in der Deutschen Gesellschaft f\u00fcr Gyn\u00e4kologie und Geburtshilfe e.V. sowie in der Deutschen Krebsgesellschaft e.V."},{"key":"6804_CR13","first-page":"403","volume":"17","author":"M Banys-Paluchowski","year":"2022","unstructured":"Banys-Paluchowski M, Thill M, K\u00fchn T, Ditsch N, Heil J, W\u00f6ckel A, Fallenberg E, Friedrich M, K\u00fcmmel S, M\u00fcller V et al (2022) (2022) AGO breast committee recommendations: surgical therapy update, AGO empfehlungen zur operativen therapie des mammakarzinoms: update 2022. GebFra. 17:403","journal-title":"GebFra."},{"key":"6804_CR14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","volume":"261","author":"M Donker","year":"2015","unstructured":"Donker M, Straver ME, Wesseling J, Loo CE, Schot M, Drukker CA, van Tinteren H, Sonke GS, Rutgers EJ, Vrancken Peeters MJ (2015) Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg 261:378\u2013382. https:\/\/doi.org\/10.1097\/SLA.0000000000000558","journal-title":"Ann Surg"},{"key":"6804_CR15","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1245\/s10434-019-07915-6","volume":"26","author":"A Glaeser","year":"2019","unstructured":"Glaeser A, Sinn HP, Garcia-Etienne C, Riedel F, Hug S, Schaefgen B, Golatta M, Hennigs A, Feisst M, Sohn C et al (2019) Heterogeneous responses of axillary lymph node metastases to neoadjuvant chemotherapy are common and depend on breast cancer subtype. Ann Surg Oncol 26:4381\u20134389. https:\/\/doi.org\/10.1245\/s10434-019-07915-6","journal-title":"Ann Surg Oncol"},{"key":"6804_CR16","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1159\/000513037","volume":"16","author":"G Kirkilesis","year":"2021","unstructured":"Kirkilesis G, Constantinidou A, Kontos M (2021) False negativity of targeted axillary dissection in breast cancer. Breast Care. 16:532","journal-title":"Breast Care."},{"key":"6804_CR17","first-page":"1097","volume":"10","author":"S Kuemmel","year":"2020","unstructured":"Kuemmel S, Heil J, Rueland A, Seiberling C, Harrach H, Schindowski D, Lubitz J, Hellerhoff K, Ankel C, Grasshoff ST et al (2020) A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients. Ann Surg 10:1097","journal-title":"Ann Surg"},{"key":"6804_CR18","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.ejso.2021.04.034","volume":"47","author":"S Hartmann","year":"2021","unstructured":"Hartmann S, Stachs A, Gerber B, Knauerhase H, Kamin F, Kundt G, Reimer T (2021) Lost clips after targeted lymph node biopsy in breast cancer patients: follow-up of the CLIP-study. Eur J Surg Oncol 47:1907\u20131912. https:\/\/doi.org\/10.1016\/j.ejso.2021.04.034","journal-title":"Eur J Surg Oncol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06804-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-022-06804-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06804-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T17:08:16Z","timestamp":1681751296000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-022-06804-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["6804"],"URL":"https:\/\/doi.org\/10.1007\/s00404-022-06804-w","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]},"assertion":[{"value":"24 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Maggie Banys-Paluchowski received honoraria for lectures and advisory role from: Roche, Novartis, Pfizer, pfm, Eli Lilly, Onkowissen, Seagen, AstraZeneca, Eisai, AstraZeneca, Amgen, Samsung, MSD, GSK, Daiichi Sankyo, Gilead, Sirius Pintuition, Pierre Fabre,\u00a0ExactSciences, and study support from: EndoMag, Mammotome, MeritMedical, Gilead, Hologic. Jens-Uwe Blohmer received honoraria and reimbursement of travel expenses for presentations and advisory board participation from; AstraZeneca, Daiichi Sankyo, Exact Sciences, Gilead, Lilly, Novartis, Pfizer, Roche, Seagen. Other authors declare no conflicts of interest. The following authors are involved in the AXSANA study supported by EndoMag, Mammotome and MeritMedical: Maggie Banys-Paluchowski (Head of German Steering Committee and Member of Organizing Committee), Thorsten K\u00fchn (Chair and Principal Investigator), Maria Luisa Gasparri (Head of Swiss Steering Committee), Jana de Boniface (Co-Chair and Head of Swedish Steering Committee), Oreste Davide Gentilini (Co-Chair and Head of Italian Steering Committee).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Charit\u00e9 Ethics Committee (EA2\/097\/21).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}